Peripherally injected canabidiol reduces neuropathic pain in mice: Role of the 5-HT 1A and TRPV1 receptors

• Published in: Biochemical and biophysical research communications 2023-06, Vol.660, p.58
• Main Authors: Aguiar, Danielle Diniz, da Costa Oliveira, Cristina, Fonseca, Flávia Cristina Sousa, de Almeida, Douglas Lamounier, Campos Pereira, William Valadares, Guimarães, Francisco Silveira, Perez, Andrea Castro, Duarte, Igor Dimitri Gama, Romero, Thiago Roberto Lima
• Format: Article
• Language: English
• Subjects: Analgesics - pharmacology; Analgesics - therapeutic use; Animals; Cannabidiol - pharmacology; Cannabidiol - therapeutic use; Disease Models, Animal; Mice; Neuralgia - drug therapy; Receptor, Serotonin, 5-HT1A; Serotonin; TRPV Cation Channels
• ISSN: 1090-2104
• DOI: 10.1016/j.bbrc.2023.04.022

Cannabidiol (CBD) is the most abundant non-psychoactive component found in plants of the genus Cannabis. Its analgesic effect for the treatment of neuropathy has been widely studied. However, little is known about its effects in the acute treatment when Cannabidiol is administered peripherally. Because of that, this research was aimed to evaluate the antinociceptive effects of the CBD when administered peripherally for the treatment of acute neuropathic pain and check the involvement of the 5-HT and the TRPV1 receptors in this event. Neuropathic pain was induced with the constriction of the sciatic nerve while the nociceptive threshold was measured using the pressure test of the mouse paw. The technique used proved to be efficient to induce neuropathy, and the CBD (5, 10 and 30 μg/paw) induced the antinociception in a dosage-dependent manner. The dosage used that induced a more potent effect (30 μg/paw), did not induce a systemic response, as demonstrated by both the motor coordination assessment test (RotaRod) and the antinociceptive effect restricted to the paw treated with CBD. The administration of NAN-190 (10 μg/paw), a selective 5-HT receptor antagonist, and SB-366791 (16 μg/paw), a selective TRPV1 antagonist, partially reversed the CBD-induced antinociception. The results of the research suggest that the CBD produces the peripheral antinociception during the acute treatment of the neuropathic pain and it partially involved the participation of the 5-HT and TRPV1 receptors.